Hikma sales in line with forecast

Jordanian group Hikma Pharmaceuticals reported a 10.4 per cent rise in first-half sales to £241.3m, in line with forecasts. First-half sales and profit were hit by political upheaval in the Middle East and north Africa. The Amman-based company expects to resume normal business in Libya by the end of the year as the country becomes the latest in the region to recover from political turmoil. Operating profit fell 34 per cent to £29.9m, reflecting lower margins due to loss of high-profit lines.